Effects of chronic GRN163L on telomere maintenance.

<p>Cells were treated every 2–3 days with no drug (CTR), mismatch oligo (MIS) or GRN163L (GRN). A–B) Southern blot analysis of the telomeres. At the indicated population doubling (PD), genomic DNA samples were collected and subsequently processed for telomere size measurements, as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0085155#pone-0085155-g001" target="_blank">Figure 1A</a>. C–D) Telomere size measurements. Median telomere sizes are shown for the drug- and control-treated CAPAN1 and CD18 cells. E) Detection of ALT by quantitative PCR. Samples tested included CAPAN1 and CD18 cells treated with no drug (CTR), mismatch oligo (MIS) and GRN163L (GRN), all of which harvested at the end of the growth curves presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0085155#pone-0085155-g003" target="_blank">Figure 3</a>. Also included were stocks of CAPAN1, CD18 and VA13 cells. Samples were tested in triplicate with (+) and without (−) the Φ29 DNA polymerase. A representative dot blot is shown.